Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback